Issues in Oncology
Supportive Care

Hearing Loss

We received several pages in quick succession before we even saw the patient in the clinic. Audiology paged immediately after their visit to report that, Liza, a 6-year-old girl with high-risk neuroblastoma...

 

Hematologic Malignancies

Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL

Advances in cancer treatment have been nothing short of breathtaking in recent years. Among the most important has been the advent of effective oral therapies, marking a significant change in the way many patients receive...

 

Lung Cancer

Immunotherapy Benefits Survival, Improves Safety, vs Platinum-Based Chemotherapy for PD-L1–Expressing NSCLC

Immunotherapy with pembrolizumab (Keytruda) improved overall survival compared with investigator’s choice of platinum-based chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer...

 


Advertisement
Head and Neck Cancer

Mobile and Sensor Technology May Lead to Reduced Symptoms of Head and Neck Cancer and Its Treatment

A randomized clinical trial evaluating the use of mobile and sensor technology to remotely monitor symptoms in patients receiving radiation therapy for head and neck cancer found that use of this technology reduced the severity of symptoms related to cancer and its treatment compared with usual care. According to...

 

Geriatric Oncology

Geriatric Assessment Improves Communication Between Oncologists and Older Patients

A federally funded randomized study demonstrated that use of geriatric assessment in the routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns...

 


More Top Stories

Skin Cancer

Paolo A. Ascierto, MD, on Melanoma: Results From the COLUMBUS Trial

Issues in Oncology
Supportive Care

Hearing Loss

The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Advertisement

ASCO/CAP Clinical Practice Guideline Focused Update on HER2 Testing in Breast Cancer

As reported in the Journal of Clinical Oncology by Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and colleagues, ASCO and the College of American Pathologists (CAP) have issued a clinical practice guideline focused update on HER2 testing in breast cancer....

Head and Neck Cancer

Manisha H. Shah, MD, on Thyroid Cancer: Advances in Precision Medicine

John V. Cox Reflects on 10 Years as Editor-in-Chief of the Journal of Oncology Practice

John V. Cox, DO, FASCO, of the Parkland Hospital and Health System/University of Texas Southwestern Medical Center, has served as the Editor-in-Chief of the Journal of Oncology Practice (JOP) since 2008. As a member of the journal’s inaugural Editorial Board, he has seen the publication evolve...

‘Pearls of Wisdom’ for Leadership and Success in Academic Medicine Gathered Over a 35-Year Career

Dr. Hayes, ASCO President 2016–2017, is Professor of Internal Medicine; Stuart B. Padnos Professor in Breast Cancer; and Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, Ann Arbor. AS I COMPLETE my 3-year term as ASCO President, I am...

Study Finds Recent-Onset Type 2 Diabetes May Be Early Manifestation of Pancreatic Cancer

According to the American Cancer Society, pancreatic cancer is one of the most deadly cancers, with an overall 5-year survival rate of just 8%, mainly because the vast majority of patients, about 80%, are diagnosed at a late stage of disease. Research has shown that identification of high-risk ...

Multiple Myeloma

Aviva C. Krauss, MD, on Multiple Myeloma: Treatment Trials Analysis

Breast Cancer

Studies Challenge Relevance of Genetic Testing Guidelines for Breast Cancer

NEW RESEARCH suggests that current genetic testing guidelines for breast cancer are far too restrictive, excluding nearly half of high-risk patients. According to a pair of studies presented at the 2018 American Society of Breast Surgeons (ASBrS) Annual Meeting, women with breast cancer who did not ...

Advertisement

EHA 2018: Tazemetostat in Relapsed or Refractory Follicular Lymphoma

Positive interim data were recently presented from an ongoing phase II study of tazemetostat—a potent, selective, orally available EZH2 inhibitor—as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, presented by Salles et al at the 23rd Annual...


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.